Unilife — Q2 FY2014 Earnings Presentation
9 slides from Unilife's earnings presentation, Feb 5, 2014
Slide 1: Fiscal Year 2014 Second Quarter Earnings Call
Fiscal Year 2014 nd Quarter Earnings Call Exhibit 99.2 February 3, 2014
Slide 2: Cautionary Note Regarding Forward-Looking Statements
This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-lo
Slide 3: Introduction to Q214 Earnings Call
Introduction to Q214 Earnings Call
Slide 4: Commercial contracts with pharmaceutical partners
Unifill Supply Contract with Hikma for Generic Injectables ~ Received first $SMM in Q214 - Received first payments of $15MM expected during CY14 Ocu-ject™ Contract with Global Ophthalmic Leader ~ Seeking to use Ocu-ject with target drug injected into eye -Payments commencing Q314 Contract with Novar
Slide 5: An Expanding Commercial Pipeline
An Expanding Commercial Pipeline Multiple customers pursuing multiple products across multiple platforms Unifill Finesse™ Unifill® Unifill Nexus™ Unifill Allure™ Unifill Select™ AutoMix Presto™ EZMix Genesis™ EZMix Engage™ EZMix Genesis™ Precision-Therapy™ Wearable Injector Flex-Therapy ™ Wearable I
Slide 6: Financial Data
Three Months Ended December 31, Six Months Ended December 31, 2013 2012 2013 2012 Financial Data • Revenue growth of 411% compared to same period prior year • Period of sequential revenue growth quarter to quarter continues • Net loss per share (net and adjusted) is narrowing • Reducing SG&A, contin
Slide 7: Doubling our cleanroom production space in York, PA
Existing clean room space Installation of new clean rooms Doubling our cleanroom production space in York, PA
Slide 8: Building shareholder value
Building shareholder value Sanofi MedImmune Hikma Biodel Novartis Others • Commercial supply contracts • Customization and clinical supply contracts • Revenue from customers Device sales, customization programs, upfront fees • Debt financing • New clean rooms • Continued expansion production capacit
Slide 9: Questions
Questions